mf101
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Feb 1, 2006 (NCT00454441)
Timeline
Indications
Mechanism of action
- Estrogen receptor betaAGONIST
ESR2 agonist
Herbal preparation, most active estrogenic compound in MF101 is the flavanone liquiritigenin which is a Erbeta selective agonist ( http://en.wikipedia.org/wiki/Liquiritigenin, PMC2277338)
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545411 ↗
Also known as
- mf101
- mf101
- mf101
- mf-101
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00906308 | Phase 3 | Oct 1, 2011 | Bionovo |
| NCT01300078 | Phase 1 | Mar 1, 2011 | Bionovo |
| NCT00453297 | Phase 1 | Oct 1, 2006 | Bionovo, University of Colorado, Denver |
| NCT00119665 | Phase 2 | Feb 1, 2006 | Bionovo, University of California, San Francisco |
| NCT00454441 | Phase 2 | Feb 1, 2006 | Bionovo, University of Minnesota |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bionovo | For profit | 5 | 5 | 3 | 2006 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Colorado, Denver | Academic/Hospital | 1 | 0 | 1 | 2006 |
| University of Minnesota | Academic/Hospital | 1 | 0 | 1 | 2006 |
4 organizations
Page 1 / 1